Characteristics of patients included in SpA-Net as of February 2019
| Variable | Total group (N=1069) | Completed, n (%) |
| Age, years | 54.9 (14.1) | 1069 (100.0) |
| Male, n (%) | 560 (52.4) | 1069 (100.0) |
| Symptom duration, years | 16.0 (11.3) | 528 (49.4) |
| HLA-B27-positive, n (%) | 300 (46.2) | 650 (60.8) |
| Diagnosis* | 1069 (100.0) | |
| Axial SpA, n (%) | 339 (31.7) | |
| Peripheral SpA, n (%) | 96 (9.0) | |
| Axial and peripheral SpA, n (%) | 55 (5.1) | |
| Psoriatic arthritis, n (%) | 510 (47.7) | |
| Reactive arthritis, n (%) | 5 (0.5) | |
| IBD-associated arthritis, n (%) | 28 (2.6) | |
| Undifferentiated SpA, n (%) | 36 (3.4) | |
| ASDAS-CRP | 2.3 (1.0) | 500 (46.8) |
| BASDAI | 4.3 (2.2) | 640 (59.9) |
| BASFI | 3.3 (2.5) | 550 (51.4) |
| HAQ-S | 0.7 (0.6) | 465 (43.5) |
| VAS pain | 3.9 (2.6) | 706 (66.0) |
| Patient global | 4.0 (2.6) | 674 (63.0) |
| Physician global | 1.6 (1.7) | 693 (64.8) |
| SJC | 0.5 (1.3) | 606 (56.7) |
| TJC | 1.1 (3.1) | 606 (56.7) |
| SF-36-PCS | 39.9 (10.0) | 551 (51.5) |
| SF-36-MCS | 48.8 (11.3) | 549 (51.4) |
| EQ-5D | 0.8 (0.2) | 382 (35.7) |
| ASAS-HI | 5.7 (3.4) | 382 (35.7) |
| Medication use, current† | 1021 (95.5) | |
| NSAID, n (%) | 554 (54.3) | |
| csDMARD, n (%) | 418 (40.9) | |
| bDMARD, n (%) | 391 (38.3) | |
| tsDMARD, n (%) | 2 (0.2) |
Values expressed as mean (SD) unless stated otherwise. If a patient had multiple scores on an instrument, the first score since enrolment in SpA-Net was used.
*Clinical diagnosis as made by the rheumatologist.
†Percentages apply to population with registered medication. In 48 patients (4.5%), no medication was registered.
ASAS-HI, Assessment of SpondyloArthritis International Society Health Index;ASDAS, Ankylosing Spondylitis Disease Activity Score;BASDAI, Bath Ankylosing Spondylitis Disease Activity Index;BASFI, Bath Ankylosing Spondylitis Functional Index;bDMARD, biological disease-modifying antirheumatic drug; CRP, C reactive protein;csDMARD, conventional synthetic disease-modifying antirheumatic drug; EQ-5D, EuroQoL-5D;HAQ-S, Health Assessment Questionnaire for Spondyloarthropathies;HLA-B27, human leucocyte antigen B27;IBD, inflammatory bowel disease;MCS, Mental Component Summary; NSAID, non-steroidal anti-inflammatory drug; PCS, Physical Component Summary; SF-36, 36-Item Short Form Health Survey;SJC, swollen joint count;SpA, spondyloarthritis;TJC, tender joint count;tsDMARD, targeted synthetic disease-modifying antirheumatic drug;VAS, Visual Analogue Scale.